CEO, TARSUS PHARMACEUTICALS
WHY: Executive of Irvine-based development-stage drugmaker with an initial focus on eye care. Firm went public in 2020.
IN THE NEWS: In May raised $75.6M in a secondary offering due to strong investor interest, among the largest fundraising deals in OC for 2022 of either public or private sectors. NOTABLE: Developing TP-03, a therapeutic to treat Demodex blepharitis, a type of ocular disease that affects some 25M Americans and as of mid-2022 had no FDA approved treatment.
QUOTABLE: “We are one step closer to providing a solution to eyecare professionals and patients that can resolve this disease.”
